192 related articles for article (PubMed ID: 28889375)
1. A Versatile Assay for Detection of Aberrant DNA Methylation in Bladder Cancer.
Tommasi S; Besaratinia A
Methods Mol Biol; 2018; 1655():29-41. PubMed ID: 28889375
[TBL] [Abstract][Full Text] [Related]
2. MIRA-seq for DNA methylation analysis of CpG islands.
Jung M; Kadam S; Xiong W; Rauch TA; Jin SG; Pfeifer GP
Epigenomics; 2015 Aug; 7(5):695-706. PubMed ID: 25881900
[TBL] [Abstract][Full Text] [Related]
3. The MIRA method for DNA methylation analysis.
Rauch TA; Pfeifer GP
Methods Mol Biol; 2009; 507():65-75. PubMed ID: 18987807
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation profiling using the methylated-CpG island recovery assay (MIRA).
Rauch TA; Pfeifer GP
Methods; 2010 Nov; 52(3):213-7. PubMed ID: 20304072
[TBL] [Abstract][Full Text] [Related]
5. Alterations of DNA methylome in human bladder cancer.
Besaratinia A; Cockburn M; Tommasi S
Epigenetics; 2013 Oct; 8(10):1013-22. PubMed ID: 23975266
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer.
Marsit CJ; Koestler DC; Christensen BC; Karagas MR; Houseman EA; Kelsey KT
J Clin Oncol; 2011 Mar; 29(9):1133-9. PubMed ID: 21343564
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation in bladder cancer: biological pathways and translational applications.
Sánchez-Carbayo M
Tumour Biol; 2012 Apr; 33(2):347-61. PubMed ID: 22274923
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
[TBL] [Abstract][Full Text] [Related]
9. Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer.
Rauch T; Pfeifer GP
Lab Invest; 2005 Sep; 85(9):1172-80. PubMed ID: 16025148
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic markers of urothelial cancer based on DNA methylation analysis.
Chihara Y; Kanai Y; Fujimoto H; Sugano K; Kawashima K; Liang G; Jones PA; Fujimoto K; Kuniyasu H; Hirao Y
BMC Cancer; 2013 Jun; 13():275. PubMed ID: 23735005
[TBL] [Abstract][Full Text] [Related]
11. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine.
Chen PC; Tsai MH; Yip SK; Jou YC; Ng CF; Chen Y; Wang X; Huang W; Tung CL; Chen GC; Huang MM; Tong JH; Song EJ; Chang DC; Hsu CD; To KF; Shen CH; Chan MW
BMC Med Genomics; 2011 May; 4():45. PubMed ID: 21599969
[TBL] [Abstract][Full Text] [Related]
12. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients.
Friedrich MG; Weisenberger DJ; Cheng JC; Chandrasoma S; Siegmund KD; Gonzalgo ML; Toma MI; Huland H; Yoo C; Tsai YC; Nichols PW; Bochner BH; Jones PA; Liang G
Clin Cancer Res; 2004 Nov; 10(22):7457-65. PubMed ID: 15569975
[TBL] [Abstract][Full Text] [Related]
13. DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression during multistage urothelial carcinogenesis.
Nakagawa T; Kanai Y; Ushijima S; Kitamura T; Kakizoe T; Hirohashi S
J Urol; 2005 May; 173(5):1767-71. PubMed ID: 15821584
[TBL] [Abstract][Full Text] [Related]
14. Promoter methylation of DNA damage repair (DDR) genes in human tumor entities:
Mijnes J; Veeck J; Gaisa NT; Burghardt E; de Ruijter TC; Gostek S; Dahl E; Pfister D; Schmid SC; Knüchel R; Rose M
Clin Epigenetics; 2018; 10():15. PubMed ID: 29445424
[TBL] [Abstract][Full Text] [Related]
15. Aberrant Methylation of Suppressor of Cytokine Signaling 1 (SOCS1) Gene as a Biomarker for Early Prediction and Diagnosis of Bladder Cancer.
Guan H; Li X; Lu J; Meng L; Guo Y; Dong J; Rong S; Zhao F; Shen H
Clin Lab; 2020 May; 66(5):. PubMed ID: 32390384
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers.
Reinert T; Modin C; Castano FM; Lamy P; Wojdacz TK; Hansen LL; Wiuf C; Borre M; Dyrskjøt L; Orntoft TF
Clin Cancer Res; 2011 Sep; 17(17):5582-92. PubMed ID: 21788354
[TBL] [Abstract][Full Text] [Related]
17. Epigenetics application in the diagnosis and treatment of bladder cancer.
Harb-de la Rosa A; Acker M; Kumar RA; Manoharan M
Can J Urol; 2015 Oct; 22(5):7947-51. PubMed ID: 26432963
[TBL] [Abstract][Full Text] [Related]
18. The role of deoxyribonucleic acid methylation in development, diagnosis, and prognosis of bladder cancer.
Gonzalgo ML; Datar RH; Schoenberg MP; Cote RJ
Urol Oncol; 2007; 25(3):228-35. PubMed ID: 17483020
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma.
Sanford T; Meng MV; Railkar R; Agarwal PK; Porten SP
Clin Epigenetics; 2018; 10():19. PubMed ID: 29456764
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic biomarkers of common urological cancers based on aberrant DNA methylation.
Peng D; Ge G; Xu Z; Ma Q; Shi Y; Zhou Y; Gong Y; Xiong G; Zhang C; He S; He Z; Li X; Ci W; Zhou L
Epigenomics; 2018 Sep; 10(9):1189-1199. PubMed ID: 30182734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
